ATE546524T1 - Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür - Google Patents

Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür

Info

Publication number
ATE546524T1
ATE546524T1 AT08719320T AT08719320T ATE546524T1 AT E546524 T1 ATE546524 T1 AT E546524T1 AT 08719320 T AT08719320 T AT 08719320T AT 08719320 T AT08719320 T AT 08719320T AT E546524 T1 ATE546524 T1 AT E546524T1
Authority
AT
Austria
Prior art keywords
libraries
scfv antibodies
producing active
active scfv
producing
Prior art date
Application number
AT08719320T
Other languages
English (en)
Inventor
Pierre Martineau
Etienne Weiss
Original Assignee
Inst Nat Sante Rech Med
Univ Pasteur
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Pasteur, Centre Nat Rech Scient filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE546524T1 publication Critical patent/ATE546524T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1093General methods of preparing gene libraries, not provided for in other subgroups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/80Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08719320T 2007-03-15 2008-03-17 Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür ATE546524T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89494707P 2007-03-15 2007-03-15
PCT/IB2008/000628 WO2008110914A2 (en) 2007-03-15 2008-03-17 Methods for producing active scfv antibodies and libraries therefor

Publications (1)

Publication Number Publication Date
ATE546524T1 true ATE546524T1 (de) 2012-03-15

Family

ID=39760160

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08719320T ATE546524T1 (de) 2007-03-15 2008-03-17 Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür

Country Status (7)

Country Link
US (2) US20090143247A1 (de)
EP (1) EP2134841B9 (de)
JP (1) JP5385796B2 (de)
AT (1) ATE546524T1 (de)
CA (1) CA2681170C (de)
ES (1) ES2384006T3 (de)
WO (1) WO2008110914A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459591B (zh) * 2009-05-20 2015-05-13 诺维莫尼公司 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法
WO2011116276A2 (en) * 2010-03-18 2011-09-22 Matthew Delisa Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates
US20110250642A1 (en) * 2010-04-12 2011-10-13 Sorrento Therapeutics Method for Displaying Antibodies
EP2752487A1 (de) 2013-01-03 2014-07-09 Sanofi Intrazelluläres Phänotypen-Screening
WO2015133882A1 (ko) * 2014-03-07 2015-09-11 사회복지법인 삼성생명공익재단 ScFv 항체 라이브러리, 이의 제조방법 및 이를 이용한 ScFv 항체 스크리닝 방법
IL275239B2 (en) 2017-12-11 2026-03-01 Abalone Bio Inc Yeast presentation of proteins in the subplasmic space
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
CA3189601A1 (en) 2020-07-24 2022-01-27 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
CN120303407A (zh) 2022-05-17 2025-07-11 恩维洛普治疗有限责任公司 用于有效体内递送的组合物和方法
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JP2002508940A (ja) 1998-03-13 2002-03-26 デイナ−ファーバー キャンサー インスティチュート,インコーポレイテッド ヒト化抗体およびその使用
US6058338A (en) 1999-02-12 2000-05-02 Qualcomm Incorporated Method and apparatus for efficient GPS assistance in a communication system
GB2344886B (en) * 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
ATE273323T1 (de) 1999-12-28 2004-08-15 Esbatech Ag INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
US20040096826A1 (en) 2002-01-30 2004-05-20 Evans Glen A. Methods for creating recombination products between nucleotide sequences
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof

Also Published As

Publication number Publication date
CA2681170A1 (en) 2008-09-18
JP5385796B2 (ja) 2014-01-08
US8841238B2 (en) 2014-09-23
EP2134841B9 (de) 2014-06-11
EP2134841A2 (de) 2009-12-23
JP2010521447A (ja) 2010-06-24
US20090143247A1 (en) 2009-06-04
EP2134841B1 (de) 2012-02-22
CA2681170C (en) 2017-10-31
US20100167957A1 (en) 2010-07-01
WO2008110914A3 (en) 2009-02-26
WO2008110914A2 (en) 2008-09-18
ES2384006T3 (es) 2012-06-28

Similar Documents

Publication Publication Date Title
ATE546524T1 (de) Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür
WO2009112245A9 (en) Antibody against the csf-1 r
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
LTPA2017040I1 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
CR9562A (es) Anticuerpos anti-cd40 humanizados y sus metodos de uso
PH12013502230A1 (en) Multispecific antibodies
LTPA2016031I1 (lt) Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai
DE602006013029D1 (de) Anti-egfr-antikörper
ATE469908T1 (de) Verfahren zur herstellung von pimecrolimus
MX350375B (es) Moleculas de union especificas de virus sincitial respiratorio y medios para producirlas.
DK2824183T3 (da) Fremgangsmåde til fremstilling af bispecifikke antistoffer
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
ATE554105T1 (de) Veränderte antikörper
MX347020B (es) Anticuerpo contra el csf-1r.
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
DK201100184U1 (da) Method for immunizing an avian species
WO2008027236A3 (en) Multispecific antibodies
CY1113074T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
CY1114926T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
ATE464908T1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
NO20084878L (no) Humanisert C-kit antistoff
ATE543910T1 (de) Verfahren und materialien zur herstellung von simvastatin und verwandten verbindungen
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
EP4087862A4 (de) Antitigit-antikörper, multispezifische antikörper, die dieseelben umfassen, und verfahren zur verwendung derselben